Clinical Trial Detail

NCT ID NCT04169737
Title Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Acalabrutinib + Obinutuzumab + Venetoclax

Age Groups: adult senior

No variant requirements are available.